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Abstract
While the etiology is unknown, serotonin and glutamate G protein-coupled receptors (GPCR)
neurotransmission dysfunctionality is characteristic of schizophrenia. Previous findings
demonstrated that the serotonin 5-hydroxytryptamine 2A (5-HT2A) receptor and the metabotropic
glutamate 2 (mGlu2) receptor assemble into a heteromeric complex; however, little is known of
the complete structural interface of the heteromer. Through a mutational-based approach,
previous research identified Transmembrane domain 4 (TM4) as being responsible for mediating
heteromerization in mGlu2 before determining the particular amino acids responsible for the
interface. A similar technique was used in this investigation to determine which component of 5HT2A is responsible for the heterodimeric interface. Here, I identified four residues at the Nterminal of transmembrane domain four essential for the 5-HT2A receptor to form a GPCR
heteromer with the mGlu2 receptor in HEK-293 cells. Substitution of these residues
(phenylalanine 4.43, leucine 4.44, isoleucine 4.47, and alanine 4.48) leads to a significant
reduction of 5-HT2A·mGlu2 receptor complex formation. This finding offers potential targets for
future photo-crosslinking investigations to identify the particular residues within the 5-HT2A
responsible for mediating the heteromeric interface of the 5-HT2A·mGlu2 complex.
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Chapter 1: Introduction
Schizophrenia
Schizophrenia affects 0.3-1.1% of the population and is a persistent, severe, and debilitating
mental illness with long-term consequences for patients and their families (Howes and Kapur,
2009). Life expectancy may be reduced by as much as 15 years in schizophrenia patients, with
morbidity being considerably more significant than with illnesses such as pulmonary and
cardiovascular sickness (Saha et al., 2007; Olfson, 2015). A significant contributor to this loss of
life is suicide, with studies estimating individuals with schizophrenia have a lifetime suicide risk
of 5-10%. (Hor, 2010; Freedman, 2003). However, mortality should not be the sole measure of
severity of a disease, as it is not representative of the hardships faced by an individual with a
given condition. Disability-adjusted life years (DALY) can be used instead to provide a metric
that quantifies the overall burden of illnesses. In conjunction with the World Health Organization
and the World Bank, DALY was pioneered by Christopher, Murray, and Lopez, resulting in the
first Global Burden of Disease (GBD) study in 1990. According to the most recent GBD study in
2016, schizophrenia accounts for 1.7% of the total DALYs globally and carries the highest
disability weight of all disorders in the GBD (Charlson et al., 2018; Salomon et al., 2015).
Economically, schizophrenia was estimated to cost the United States $155 billion in 2013
through both direct and indirect healthcare costs, totaling $44,773 per individual patient based on
a prevalence of 1.0%. When compared to major depressive disorder (MDD), which affects 8.1%
of the United States population and indirect costs $210.5 billion ($4,071.8 per MDD patient), the
severe economic burden schizophrenia imposes becomes more evident (Greenberg et al., 2015;
Wander, 2020)
7

Schizophrenia, which usually develops during adolescence or early adulthood, can present itself
with a wide variety of symptoms, the hallmarks being changes in perception, thought, and
behavior. (Owen et al., 2016).
The DSM-5 diagnostic criteria for schizophrenia include hallucinations (i.e., sensory perceptions
in the absence of concurrent sensory stimuli), delusions (i.e., beliefs firmly maintained despite
significant evidence of them being not true), disorganized speech and behavior (e.g., grossly
disorganized, frequent derailment or incoherence), and negative symptoms (characterized by loss
or deficits of features that are present in healthy individuals) (American Psychiatric Association,
2013). Disability often results from both a combination of negative symptoms and cognitive
symptoms (e.g., learning and attention disorders). In addition, relapse may occur because of
positive symptoms (characterized by an excess or distortion of normal function), such as
suspiciousness, delusions, and hallucinations (Crismon et al,. 2014; Patel et al,. 2014 ).
While the etiology of schizophrenia is unknown, it has been demonstrated to involve a variety of
structural and neurochemical dysfunctions in multiple brain regions (Ripke et al., 2013), of
which abnormalities in neurotransmitter systems have been proposed to contribute significantly
(Brish et al., 2014).
Overactive dysregulation in the dopaminergic neurotransmitter (DA) system has been the
predominant pathophysiological hypothesis of schizophrenia. This stemmed from two
observations: 1) first-generation “typical” antidopaminergic antipsychotics primarily as D2
antagonists 2) indirect D2 agonists (amphetamine, phencyclidine, etc.,) induce psychotomimetic
effects or exacerbate schizophrenic symptoms by increasing dopamine activity in the subcortical
and limbic regions. This overactivity has also been supported by human postmortem findings of
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the frontal cortex, which observed increases in D2 receptor expression and D2 mRNA levels,
with increased activity in the mesolimbic pathway (Davis et al., 1991; Abi-Dargham et al., 2000;
Tallerico et al., 2001).
The roles of other neurotransmitters such as glutamate (Glu) and serotonin (5-HT) in the
neuropathology of schizophrenia have started to gain particular attention as being the primary
target of second-generation antipsychotics (Miyamoto et al., 2005; Conn et al., 2009).
Furthermore, the psychotomimetic effects of drugs that antagonize the glutamate and serotonin
signal recapitulate schizophrenia ethology to a much more accurate extent than drugs that simply
stimulate dopamine signaling (Kapur et al., 2002; Halberstadt et al., 2011).
Many neurotransmitters involved in schizophrenia act through metabotropic G protein-coupled
receptors (GPCRs). Serotonin, dopamine, and glutamate are traditionally recognized as
molecular targets in this investigation (Patil S et al., 2007; Kwan C et al., 2021).

General GPCR characteristics
G protein-coupled receptors (GPCRs) are the largest family of cell-surface receptors in the
human genome that function to mediate slow synaptic transmission by modulating intracellular
signal transduction, through which they regulate an incredible range of physiological processes
ranging from cell growth to neurotransmission (Ji et al., 1998; Levoye A et al., 2006;
Grundmann et al., 2018).
GPCRs share a common structure comprised of a single polypeptide chain with seven
transmembrane (TM) α-helix domains, an extracellular amino-terminal, an intracellular
carboxyl-terminal tail, and three cytosolic and extracellular loops. The G proteins associated with
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GPCRs are heterotrimeric comprised of an: α-subunit, β-subunit, and γ-subunit. By interacting
with other membrane proteins involved in signal transduction, these subunits relay messages
within the cell (Rosenbaum et al., 2009). While sharing distinct structural characteristics, GPCRs
have been classified into five major families according to phylogenetic criteria: Family A
(rhodopsin-like), Family B (secretin receptor family), Family C (metabotropic glutamate
receptors), Adhesion, and Frizzled/Taste2. Sequence homology within these families is at least
40%, with the greatest homology at the transmembrane domain. (Vassilatis et al., 2003;
Bjarnadóttir et al., 2006)
GPCRs can further be categorized by downstream signaling pathways depending on the α
subunit: Gi/o, Gs/olf, Gq/11, and G12/13. As the name suggests, in response to ligand binding, GPCRs
activate heterotrimeric guanine nucleotide-binding proteins (G proteins), stimulation of which
results in a dissociation of the Gα subunit from the Gβγ dimer and allows the subunits to activate
or inhibit various effectors. Gs/olf (stimulatory) and Gi/o (inhibitory) pathways regulate cAMPdependent signaling by either stimulating or inhibiting adenyl cyclase activity. The Gq/11 coupled
pathway operates via phospholipase C-β enzymes, which hydrolyzes phosphatidylinositol 4,5bisphosphate (PIP2) to diacylglycerol (DAG) and inositol 1,4,5- trisphosphate (IP3). Hydrophilic
IP3 diffuses into the cell and acts as a second messenger to release stored calcium from the
endoplasmic reticulum lumen into the cytoplasm. Whereas DAG acts as a second messenger that
activates protein kinase C (PKC). G12/13 stimulates small GTPase downstream signaling
(Moghaddam et al., 2004; Liu et al., 2021).
Comprehensive research on GPCRs led to the identification of an orthosteric site for endogenous
ligand binding as well as several allosteric sites that can modulate response: Positive Allosteric
Modifiers (PAMS) and Negative Allosteric Modifiers (NAMS) (Foster et al., 2017). Due to their
10

central roles in many cellular functions and numerous binding sites, GPCRs are an important
therapeutic target, with different reports suggesting that between 30 and 40% of FDA-approved
drugs target GPCRs (Wise et al., 2002; Brink et al., 2004).
Initially, GPCRs were thought to exist and function as monomeric structural units that couple to
G-proteins in a 1:1 stoichiometric ratio. (Liang Y et al., 2017) This model is supported by
evidence that purified monomeric β2-adrenoreceptor (Family A) reconstitutes in a phospholipid
bilayer is sufficient for fully functional G protein activation (Whorton et al., 2007; Kuszak et al.,
2009).
However, over the last decade, the notion that these receptors function exclusively as monomeric
proteins has been challenged, with indications that GPCRs can exist and function as dimers or
even higher-order oligomers. Investigation into Family A, D2 receptors indicated the receptor
requires two structural units to one G-protein to be maximally activated by a single bound ligand
(Han et al., 2009). Additional evidence suggests class C metabotropic Glutamate (mGlu) and
GABA receptors act as obligate homodimers, suggesting dimerization is crucial for receptor
function (Kniazeff et al., 2011).
GPCRs may also undergo heterodimerization. Initial evidence for this model came from studies
of the α2-adrenoreceptor and M3 muscarinic receptor in which two mutant chimeras were
generated with TM-6 and TM-7 exchanged between α2C and M3. This revealed that only when
co-transfecting the α2/M3 and M3/α2 chimeras resulted in stimulation, suggesting the two
receptors are intricately connected, and the presence of all transmembrane domains was
necessary and sufficient for signaling, regardless of which specific receptor they were inserted in
(Zeng et al., 2000).
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Perhaps the most eloquent example of heterodimerization is the interaction between GABAB-R1
and GABAB-R2 subunits in forming a fully functional GABAB (γ-aminobutyric acid type B)
receptor. Functional membrane receptors were created by co-expression of recombinant
GABAB-R1 and GABAB-R2 plasmids but not by expressing each recombinant plasmid alone.
Further studies exploring this model revealed GABAB-R1 appears to determine the
pharmacological properties of the receptor, while GABAB-R2 is essential for the proper
expression of GABAB-R1 on the plasma membrane. (Filippov et al., 2000; Jones et al., 2000)
Heterodimerization involving two fully functional GPCRs from distinct families has also been
well established. κ and δ opiate receptors have been shown to form a fully functional
heterocomplex receptor that exhibits distinct functional and ligand-binding characteristics
distinct from those of either receptor alone (Jordan & Devi, 1999). 5-HT2A and D2 have also
been shown to form a functional heterocomplex with ligands conveying different effects on
downstream signaling depending on whether homo- or hetero-dimers are present. (Łukasiewicz
et al., 2010) Additionally, Family A 5-HT2A and Family C mGlu2 receptors have been shown to
form a functional heterocomplex in the mammalian brain and tissue culture preparations.
(González-Maeso et al., 2008; Rives et al., 2009; Moreno et al., 2012).
There are several ways that a heterocomplex interaction can be assessed. Coimmunoprecipitation (Co-IP) assays are robust measures to determine whether two proteins
interact. Co-IP is performed by binding one of the proteins of interest with a magnetic bead, then
washing away all proteins that are not bound to the antibody-bead-protein complex, followed by
immunoblot probing for the second protein of interest. If the two proteins are part of the same
protein complex, then there would be an immunoreactive signal detected for the protein that was
not directly bound to the magnetic bead (Tang et al., 2018). However, there are also alternative
12

methods to address GPCR complex formation, including Förster (Fluorescence) Resonance
Energy Transfer (FRET) and Bioluminescence Resonance Energy Transfer (BRET). FRET is a
technique where after excitation with a laser, an excited donor molecule (e.g., cyan fluorescence
protein) transfers resonance energy to an acceptor molecule (e.g., yellow fluorescence protein),
producing a highly distance-dependent fluorescence. Therefore, this can accurately measure the
molecular proximity of two proteins at angstrom distances (10-100 Å) (Sekar et al., 2003).
BRET is a very similar technique to FRET; however, the resonance energy transfer is not
between two fluorescent proteins but rather between a bioluminescent donor and a fluorescent
acceptor and therefore does not require an excitation source (Dimri et al., 2016).

The 5-HT2A·mGlu2 Heteromeric Receptor Complex
Abnormalities in the serotonin and glutaminergic system have been observed in schizophrenia
patients compared to neuropsychiatric healthy control subjects. Postmortem and neuroimaging
studies suggest an increase in Gq/11-coupled 5-HT2A receptor density with concurrent decreases in
Gi/o-coupled mGlu2/3 receptor density and treatment with second-generation antipsychotic drugs
decreases density to control levels (Gonzalez-Maeso et al., 2008). This has similarly been
verified in a rodent model where chronic treatment with second-generation antipsychotics,
clozapine and risperidone, downregulated 5-HT2A cortical neurons. (Gonzalez-Maeso et al.,
2008; Kurita et al., 2012). Additionally, rodent studies revealed that the administration of classic
serotonergic psychedelics in mGlu2 -/- knock-out mice eliminated the hallucinogenic-specific
signaling component, suggesting this pattern of 5-HT2A, mGlu2 density may predispose
psychosis (Gonzalez-Maeso, 2008).
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Previous findings have also demonstrated cross-talk between the Gq/11-coupled 5-HT2A and the
Gi/o-coupled mGlu2 receptors, showing they form a heteromeric complex via which the 5HT2A·mGlu2 complex incorporates both serotonin and glutamate signaling to modulate
downstream signaling and behavioral changes (Moreno, 2016). Further studies have indicated
that in response to endogenous ligands (glutamate and serotonin), the 5-HT2A·mGlu2
heteromeric complex functions to establish a Gi/o-Gq/11 balance, which is believed to underlie the
therapeutic action of mGlu2 activators and 5-HT2A antagonists. Classic psychedelics such as
LSD, Mescaline, and Psylocibin, have been shown to shift the signaling balance towards a more
psychosis-like condition, while on the other hand, second-generation antipsychotics have been
shown to recover the Gi/o/Gq/11 imbalance (Fribourg et al., 2011).
This heteromeric complex allows for a plethora of therapeutic targets to allow for more
deliberate modulation intracellular signal, rather than each individual GPCRs (Wootten et al.,
2018).

Mapping the Heteromeric Interface of 5HT2A-mGlu2
Within the 5-HT2A·mGlu2 complex, the structural mechanisms responsible for forming the
oligomer are poorly understood, as is/are the molecular mechanism(s) responsible for cross-talk.
In the investigation into the mechanism by which 5-HT2A·mGlu2 heterocomplex modulates
downstream signaling, the structure of the heteromeric interface must be considered. Several
studies have used a mutational-based approach to examine whether a direct mechanism
contributes to cortical cross-talk between the two receptor systems (Moreno et al., 2012)
Co-immunoprecipitation assays of human brain cortex samples and transfected HEK-293 cells
with antibody epitope tags verified 5-HT2A and mGlu2, but not mGlu3, form part of the same
14

protein complex (Gonzalez-Maeso et al., 2008). Due to the sequence homology between
mGlu2/3, mutant chimeras with non-homologous amino acid residues of mGlu3 were inserted
into mGlu2 in order to disrupt the heteromeric assembly. Through this method, researchers
identified three residues at the intracellular end of TM4 (Alaine 4.40, Alanine 4.44, and Alanine
4.48), which are necessary to form the 5-HT2A·mGlu2 receptor heterocomplex. Additionally,
when the TM4 residues of mGlu2 were inserted into the mGlu3, it was sufficient for signaling
cross-talk to occur (Moreno et al., 2012).
As there is similar discrimination found between the 5-HT2A and 5-HT2C (which does not form a
protein complex with mGlu2), additional investigations utilizing a similar mutational chimeric
method to the one described above indicated the TM4 domain of 5-HT2A is necessary for the
heterocomplex to form. (Moreno et al., 2016.)

Objective
With abundant research highlighting the biological relevance of the 5-HT2A·mGlu2
heterocomplex in modulating signaling, the complete structural interface between the two
GPCRs remains unknown.
While the residues in mGlu2 responsible for dimerization have been identified, the residues in 5HT2A remain unidentified, having only been limited down to the TM4 domain. I hypothesize that
the residues in the N-terminal half of 5-HT2A are responsible for mediating the formation of a
heterocomplex with mGlu2.
This was assessed using a heterologous expression system in human embryonic kidney cells
(HEK-293). A 5-HT2A chimera mutated to include four aligned residues from 5HT2C along the
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TM4 of 5-HT2A closest to the N terminus (5-HT2A-TM4ΔNF) was co-expressed with mGlu2 to
attempt to disrupt the binding interface of the heteromer.
The four 5-HT2A residues mutated (phenylalanine 4.43, leucine 4.44, isoleucine 4.47, and alanine
4.48) were chosen to start this investigation because these residues i) are different between 5HT2A and 5-HT2C, and ii) are located facing towards the lipid bilayer according to the recent
crystal structure of the 5-HT2A (Kimura et al., 2019)
Disruption of the heterocomplex was evaluated using a co-immunoprecipitation followed by
immunoblotting. Further characterization of the mutant chimera was also performed to confirm
level of expression, cellular localization and function homology to WT 5-HT2A.

Chapter 2: Research Methods
Plasmid Preparation, Amplification, and Sequencing of Constructs
The constructs pcDNA3.1-c-Myc-5-HT2A-mCherry and pcDNA3.1-HA-mGluR2-mCitrine,
described previously (Moreno et al., 2016), and 5-HT2A-TM4ΔNF were obtained (Kareem,
2020). The primer used for sequencing of Mutant construct (5-HT2A-TM4ΔNF) was: 5’-AGC
TGA TAT GCT GCT GGG TT -3’. Following sequence verification, constructs were
transformed into XL1-Blue Supercompetent Cells (Agilent Technologies; CN: 200236) before
purification and amplification by Plasmid Maxi Prep (QIAGEN).

Cell culture
Human Embryonic Kidney (HEK)-293 cells were used for transfection and cultured in a 5% CO2
at 37°C in Medium A, DMEM (Dulbecco’s Modified Eagle’s Medium; 4.5 g/L glucose, L-
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glutamine, sodium pyruvate) supplemented with 10% (v/v) dialyzed fetal bovine serum (dFBS)
(Thermo Fischer Scientific; CN: 26400044) and 1% (v/v) Penicillin-Streptomycin (Thermo
Fischer Scientific; CN: 15140122) (except immediately prior to transfection, as noted below).
Cells underwent passages every 2-3 days, using fresh Medium A in a ratio between 1:8 and 1:12,
to keep the cells in their exponential growth phase and never passaged higher than 20 times.

Transient Transfection of HEK 293 cells
48hr before transfection, HEK-293 cells were split and cultured in DMEM supplemented with
10% (v/v) dFBS only. All Transient transfections were conducted with Lipofectamine 3000
(Invitrogen; CN: L3000001) using a Lipofectamine 3000 to plasmid ratio of 1:1.5 and performed
according to the manufacturer’s recommendations. A total of 6 μg/plate of plasmid DNA was
used in each single transfection. This includes the individual transfection of the constructs, cMyc-5-HT2A-mCherry, and c-Myc-5-HT2A-TM4ΔNF-mCherry. A total of 12 μg of DNA was
used in each co-transfection with a plasmid ratio of (1:2), 4 μg of which were vector, 5HT2A receptor, or mutant 5-HT2A receptor DNA and 8 μg of which was DNA construct HAmGluR2-mCitrine. This includes co-transfection of constructs c-Myc-5-HT2A-TM4ΔNFmCherry with HA-mGluR2-mCitrine, and c-Myc-5-HT2A-mCherry with HA-mGluR2-mCitrine.
24hr after transfection, media was removed and replaced with DMEM supplemented with 10%
(v/v) dFBS and 1% (v/v) Penicillin-Streptomycin, for an additional 24hr before harvesting.

Cell Membrane Preparation
48 Hours following transfection, cells were harvested with Dulbecco’s Phosphate-Buffered
Saline, 1X without calcium and magnesium (DPBS) (Corning; CN: 21031CV). The resulting cell
pellets were frozen at –80°C before being prepared into membranes. A Teflon homogenizer was
17

used to homogenize the cell pellet (50 ups/downs) in 10ml Tris-HCl 1x (50 mM Tris-HCl, pH
7.4). Homogenized tissue was spun for 5 min at 1,000 × g (4°C) and the pellet was discarded.
The supernatant was spun for 15 min at 40,000 × g. Subsequent pellet was washed with 500 μl
Tris-HCl and spun again for 15 min at 40,000 × g. The pellet was resuspended in 500μl of TrisHCl and transferred to a 1.7 ml Eppendorf tube, then spun at 18,000 × g in a microcentrifuge for
15 min at 4°C. The Tris-HCl 1x was removed, and the pellet was either used or stored at −80°C
until use.

Co-immunoprecipitation
Co-immunoprecipitation was conducted using 600μg of prepared cell membrane. Protein Assay
(Bio-Rad; CN: #5000006) was performed to normalize the amount of protein. Membranes were
resuspended with 500μl RIPA buffer (50 mM HEPES, 150 mM NaCl, 5mM EDTA, and Mini
EDTA-free Protease Inhibitor Cocktail tablet (Roche Applied Sciences; CN: 04693159001), pH
7.4) and allowed to solubilize with 500μl Solubilization buffer (RIPA buffer supplemented with
1% SDS and 2% Triton X-100 (Fischer Scientific; CN: BP151-500)) by incubation on a rotating
mixer at 4 °C for 1hr. Cells were incubated on a rotating mixer with Protein A/G PLUS-Agarose
immunoprecipitation beads (Santa Cruz Biotechnology; CN: sc-2003) at 4 °C for 30 minutes to
account for non-specific binding. 100μl of the cell lysates was saved for Total Protein control,
and the remainder was then incubated with immunoprecipitation beads conjugated to c-HA-TagMouse Ab (diluted 1:1000; Cell Signaling Technology; CN: 3724) at 4 °C for 18 hours. The
beads were washed at 4 °C three times in RIPA buffer. Immunoprecipitated proteins were then
eluted from the beads by resuspension in 20 μl Solubilization buffer, followed by western
blotting.
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Western Blot
Samples were mixed with 5μl 5x Laemmli buffer and heated for 5 min at 97 °C. Proteins were
resolved by 12% SDS-PAGE and transferred to nitrocellulose membranes by electroblotting.
Nitrocellulose blots were washed with TBST (150 mM NaCl, 50 mM Tris-Cl, and 0.1% Tween
20, pH 7.6) before incubating the membrane in Blocking Buffer (TBST, 2.5% nonfat dry milk,
0.5% BSA) for 1hr at room temperature. Nitrocellulose blots were then incubated (overnight at
4° C) with c-myc-Tag-Mouse Ab (diluted 1:1000; Cell Signaling Technology; CN: 9B11).
Following six washes with TBST, blots were incubated with Anti-Mouse IgG Horseradish
peroxidase (HRP) conjugated secondary Ab (1:5000; ACCURATE Chemical Science Corp.)
After incubation, blots were washed six more times with TBST for 30 minutes and developed
using enhanced chemiluminescence detection (SuperSignal™ West Pico PLUS
Chemiluminescent Substrate; Thermo Fischer Scientific) in accordance with manufacture
instructions. Immunoreactive bands were analyzed using ChemiDoc Imaging System and Image
Lab (Bio-Rad Laboratories). Final data of Co-immunoprecipitation are expressed as a ratio of the
relative density of the 250kDa band to its respective 250 kDa total protein band. Final data for
characterization of immunoblot signal is expressed as the 250 kDa was normalized to β-actin.
Observed differences were considered statistically significant if P-values were below 0.05.

Radioligand binding
Saturation binding assays were performed with the 32μg prepared cell membranes and
[3H]ketanserin (22.8 Ci/mmol; PerkinElmer; CN: NET1233), then incubated in Tris-HCl for 1hr
at 42°C. The following [3H]ketanserin concentrations were used: 10 nM, 5 nM, 2.5 nM, 1.0 nM,
0.5 nM, 0.25 nM, 0.125 nM, 0.0625 nM, all in duplicate for total and non-specific (three reactions
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at each concentration were measured). Non-specific binding was determined by incubating the
reactions with 100μM methysergide (Tocris; CN: 1064); two samples were pooled for each
assay. Protein Assay (Bio-Rad; CN: #5000006) was performed to normalize the amount of
protein in each assay. Reactions were harvested by vacuum filtration through Glass fiber
Filtermat A (PerkinElmer) (3× 50 mM Tris-HCl, pH 7.4) and counted by liquid scintillation
using a PerkinElmer 2450 MicroBeta2. Data analyses were performed using Microsoft Excel and
GraphPad Prism v8.0 (GraphPad software, San Diego, CA, USA). KD and Bmax were determined
by a saturation binding analysis, 𝑌 =

𝐵𝑚𝑎𝑥 × 𝐾𝐷
𝐾𝐷 +𝑋

[Ca2+]i Mobilization Assay
Functional signaling was assessed by measuring Ca2+ release in the presence of serotonin
(100μM, 10μM, 1μM, 100nM, 10nM, 1nM, 0.1nM, 0nM ) in 5-HT2A-TM4ΔNF or WT 5-HT2A
cells. The day before the assay, 50,000 (5-HT2A) or 50,000 (5-HT2A-TM4ΔNF) cells/50 μL were
seeded in poly-D-lysine coated (1mg/ml) 96-well black plates (Greiner 781091). The cells were
incubated with 50μl 3 μM Fluo 4 Direct (Thermo Fisher Scientific; CN: F10471) in imaging
solution (5 mM KCl, 0.4 mM KH2PO4, 138 mM NaCl, 0.3 mM Na2HPO4, 2 mM CaCl2, 1 mM
MgCl2, 6 mM glucose, 20 mM HEPES, pH 7.4) supplemented with pluronic acid (10% solution
in DMSO) for 1 h at 37˚C, as described in the manufacturer’s instructions. Changes in
fluorescence due to intracellular Ca2+ mobilization were measured using a FlexStation® plate
reader (Molecular Devices) with λex 494 nm and λem 525 nm. Baselines were recorded every 2
s for 30 s. Serotonin was added at 30 s; reading started at 90 s after serotonin transfer, reading
every 1 s for a total of 180 s. The fluorescence was a measure of intracellular calcium and was
normalized to basal fluorescence using SoftMax Pro (Molecular Devices, Wokingham, UK).
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Functional data was analyzed by nonlinear regression to generate concentration-response curves
and EC50 values by Prism V8.0 software, (Y=Bottom + (Top-Bottom) / (1 + 10 ^ ((LogEC50X)*HillSlope)(GraphPad Software, San Diego, CA, USA).

Confocal microscopy imagine
Confocal microscopy imaging was performed on pcDNA3.1-c-Myc-5-HT2A-mCherry and
pcDNA3.1-c-Myc-5-HT2A-TM4ΔNF-mCherry transfected HEK 293 cells. Samples were fixed in
pre-cooled 4% paraformaldehyde in 1x PBS for 30 minutes, then washed twice with 1X PBS
before incubating the membrane in Blocking Buffer (1x PBS, 5% BSA) for 2hr. Cells were then
stained with 1:10,000 dilution Hoechst 3342 (20mM) (Thermo Fischer Scientific; CN: 62249)
for 15 minutes, then washed two times in Phosphate-Buffered Saline (137 mM NaCl, 2.7 mM
KCl, 8 mM Na2HPO4, and 2 mM KH2PO4) (10 minutes for each wash). Coverslips were
transferred to a microscope slide and mounted (Invitrogen ProLong™ Diamond Antifade
Mountant) for microscopic fluorescence visualization. Images were acquired using a Zeiss
LSM710 laser-scanning confocal microscope (Carl Zeiss AG, Jena, Germany) with Airyscan
(Plan-Apochromat, objective 63×, Numerical Aperture 1.4). The zoom images are digitally
cropped using the same objective at 2x zoom. Microscopy was performed at the VCU
Microscopy Facility, supported, in part, by funding from NIH-NCI Cancer Center Support
Grant P30 CA016059.
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Chapter 3: Results
Sequence alignment
Sequence analysis was performed to corroborate whether the 5-HT2A-TM4ΔNF chimera was
mutated to contain 5-HT2C TM4 N-terminal residues. All residues were identified using the
Ballesteros-Weinstein sequence-based numbering system. This revealed successful replacement
of WT 5-HT2A residues phenylalanine 4.43, leucine 4.44, isoleucine 4.47, and alanine 4.48 with
the isoleucine 4.44, methionine 4.55, alanine 4.47, and isoleucine 4.48 found in WT 5-HT2C (Fig
1).

Figure 1. 5-HT2A-TM4ΔNF sequence homology between 5-HT2A and 5-HT2C in TM4.
Amino acid sequence alignment of the transmembrane domain 4 (TM4) of Human 5-HT2A, 5HT2C, and 5-HT2A-TM4ΔNF receptors. All residues were identified by the sequence-based
numbering system by Ballesteros-Weinstein. Residues that are different between 5-HT2A and 5HT2C in N-terminal TM4 are highlighted in red, with the 5-HT2A-TM4ΔNF mutant sequence
alignment at the bottom.

Characterization by Immunoblot
To assess whether the c-myc-5-HT2A-TM4ΔNF receptor was expressing itself properly, and
there was no misfolding, immunoblot assays were performed to test whether the molecular
weight of c-myc-5-HT2A-TM4ΔNF is equivalent to 5-HT2A. Immunoblot assays were performed
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in membrane lysates of HEK-293 cells transiently transfected with these two constructs. Anti-cmyc immunoreactivity was detected as a mixture of a 53kDa band and a band of approximately
250 kDa corresponding to the size anticipated for a 5-HT2A monomer and oligomer, respectively
(Fig. 2). There was no significant difference seen in c-myc immunoreactivity between the c-myc5HT2A-TM4ΔNF and c-myc-5-HT2A 250 kDa oligomer when analyzed by Student’s unpaired t-
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test (t = 0.6098, df = 4, P > 0.05). This suggests an equivalent molecular weight of the 5-HT2A/5HT2C construct.

A)
WB: c-myc

WB: β-actin

B)

Figure 2 Immunoblot assay. A) Representative Western blot for 5-HT2A and 5-HT2A-TM4ΔNF. B)
Histogram of immunoreactivity (after normalization) of 250 kDa 5-HT2A and/or 5-HT2A-TM4ΔNF.
Normalized to β-actin. Error bars indicate S.E.M., significance determined by unpaired Student’s ttest. (n = 3; independent experiments performed in duplicate)
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5-HT2A TM4 N-terminal Residues Role in Mediating Association with mGlu2
Co-immunoprecipitation was performed using anti-HA antibodies in plasma membrane
preparations of HEK-293 cells transfected to express the HA-mGlu2 together with the c-myc5HT2A-TM4ΔNF receptors. Immunoblot analysis of co-immunoprecipitated material revealed
anti-c-myc immunoreactivity was detected at ~ 250 kDa band, this corresponding to the size of
the 5-HT2A oligomer.

A)

Figure 3. Co-immunoprecipitation 5-HT2A-TM4ΔNF + mGlu2. A) Western blots showing
results of immunoprecipitation with HA-tagged Ab, Wb c-Myc Ab. B) Histogram shows
average relative densitometric, from three replicates, normalized to the total protein control
before immunoprecipitation. Error bars indicate S.E.M. significance determined by unpaired
Student’s t-test. The figure shows representative images of three independent experiments.
Interestingly, substitution of residues F4.43, L4.44, I4.47, and A4.48, in 5-HT2A with the I4.44,
M4.55, A4.47, and I4.48 in 5-HT2C (5-HT2A-ΔTM4NF) significantly reduced coimmunoprecipitation with mGlu2 (n=3 unpaired Student’s t test (t = 4.687, df = 4, P = .009)
(Fig. 3).
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Functional Characterization of 5-HT2A-TM4ΔNF
In light of the ΔTM4NF mutation’s apparent role in mediating the heteromeric interface, further
characterization assays were performed to assess functional homology with 5-HT2A. As noted
above, 5-HT2A is a Gq/11 coupled GPCR which, when stimulated, produces a transient increase in
the concentration of intracellular Ca2+. An intracellular calcium mobilization assay performed in
c-myc-5HT2A-TM4ΔNF transfected HEK-293 cells revealed 5-HT produced a concentrationdependent increase of signal, corresponding to that observed in 5-HT2A (Fig. 4) (EC50: 5-HT2A ΔTM4NF: 5.6 nM; 5-HT2A: 6.9 nM. Emax = 5-HT2A -ΔTM4NF: 98.89; 5-HT2A: 100.2) Analyzed
by nonlinear regression to generate concentration-response curves and analysis by unpaired
Student’s t-test showed no significance (P = .997). As there was no Ca2+ mobilization detected
in untransfected HEK-293 cells, it can be assumed that the transient increase observed in Fig. 4
is due to the presence of either 5-HT2A -ΔTM4NF or 5-HT2A constructs.
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Figure 4. Ca2+ mobilization on transiently transfected HEK-293 cells with Fluo-4.
Concentration dependent Ca2+ mobilization for serotonin in transiently transfected HEK-293
cells expressing 5-HT2A-ΔTM4NF or 5-HT2A (50,000 cells/well). All concentration responses
represent the mean of two independent experiments, each performed in triplicate wells (n = 2).
The SEM values are not presented because n = 2.

Antagonist radioligand saturation
5-HT2A -ΔTM4NF and 5-HT2A membrane preparations were subjected to saturation analysis with
the high-affinity antagonist [3H]ketanserin to determine receptor density. Nonlinear analysis of
binding fitted to a saturation curve showed no significant difference in KD (binding affinity) or
Bmax (receptor density) (Bmax: 5-HT2A -ΔTM4NF: 223.0 ± 23.32 fmol/mg; 5-HT2A: 211.3 ±
27.01 fmol/mg. KD: 5-HT2A -ΔTM4NF: 6.129 ± 1.260 nM; 5-HT2A: 6.784 ± 1.648 nM) (n=3 per
group). These results further suggest 5-HT2A -ΔTM4NF expresses itself to the same extent as its
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wild-type counterpart. It should be noted there was no full saturation observed in these assays,
therefore binding was fitted to an “estimated Bmax” curve.

Figure 5. [3H] Ketanserin saturation binding. Binding saturation curves in 5-HT2A wild type
(red) and 5-HT2A -ΔTM4NF (blue). The binding of radioligand is plotted as a function of
radioligand concentration. Specific binding was obtained by subtracting non-specific binding
from total binding. All binding concentrations represent the mean – S.E.M. (n = 3; independent
experiments performed in duplicate)

Subcellular Localization of 5-HT2A-ΔTM4NF-mcherry
Finally, subcellular localization of the 5-HT2A -ΔTM4NF construct was investigated. For the 5HT2A receptor to be functional, the receptor must be trafficked into the plasma membrane to then
interact with a ligand to propagate a signal into the cell, therefore any potential changes in
trafficking due to the 5-HT2C mutations had to be investigated. To allow for easier identification,
both the WT and mutant 5-HT2A constructs contained a fluorescent c-terminal mCherry tag.
Hoechst stain was applied to identify the nucleus before fixation. Images acquired through
confocal fluorescent microscopy (Fig. 6C, 6F) show the cellular distribution of 5-HT2A-
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ΔTM4NF-mcherry is similar to the WT 5-HT2A-mcherry in HEK-293 s cells. Subcellular
localization of both receptors is predominantly distributed around the cell in the plasma
membrane with m-cherry fluorescence also detected within another unidentified subcellular
compartment(s).

Figure 6 Cytochemistry 5-HT2A-TM4ΔNF in HEK-293 cells. Confocal analysis
highlighting the presence of 5-HT2A-ΔTM4NF-mcherry receptor in transiently transfected
HEK-293 cells. The figure shows representative images of six experiments.

Chapter 4: Discussion
Although the structural interface of mGlu2 in mediating the heteromeric complex of 5HT2A·mGlu2 has been identified, the 5-HT2A heteromerization residues have only been narrowed
down to the TM4 domain. This study provides evidence for the involvement of four residues
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located at the intracellular end of TM4 within 5-HT2A in its heteromeric assembly with the
mGlu2 receptor.
These findings indicate the residues F4.43, L4.44, I4.47, and A4.48 of 5-HT2A, which are
oriented facing the lipid bilayer, play a critical role in the expression of the heteromeric complex
with mGlu2 in HEK-293 cells. Replacing these four residues with those in the TM4 of the
closely similar 5-HT2C significantly disrupts its heteromeric association with the 5-HT2A
receptor (Fig. 3A). Functional and structural assays performed in this study verify the expression
of the 5-HT2A-TM4ΔNF is homologous to 5-HT2A; therefore, the reduced signal observed in the
co-immunoprecipitation immunoblot assay can be attributed to a disruption in the heteromeric
association rather than a decrease in the level of expression. It should be noted, the sample size
used in this study was relatively small (n=3). Nevertheless, these findings suggest that Nterminal residues are critical structural components mediating heteromeric formation. It is
important to mention the present evidence does not exclude the possibility other residues not in
the N-terminal half of TM4 still maintain the heteromeric interface. It is also possible 5HT2A and mGlu2 receptors interact indirectly as a part of a larger protein complex, by way-of
scaffolding proteins, rather than interacting directly as a part of a GPCR heteromeric complex.
To verify the overall quaternary structure of the receptor had not been disrupted with the
introduction of 5-HT2C residues, Western blot assays were performed. This confirmed structure
and expression of 5-HT2A-TM4ΔNF was homologous to 5-HT2A. While two anti-myc
immunoreactive bands were detected, statistical analysis was performed only on the 250 kDa
(pentamer) signal. This was due to the co-immunoprecipitated immunoblot assay revealing no
monomeric signal, and analysis was to maintain consistency between experiments (Fig 2B).

30

Cross-talk plays a critical role in forming a Gi/Gq balance between the 5-HT2A and mGlu2
receptors. Therefore, when characterizing the 5-HT2A-TM4ΔNF mutant chimera, it was
necessary to confirm the mutation did not cause dysfunctionality in signaling. Ca2+ mobilization
confirmed that the 5-HT2A-TM4ΔNF mutant forms a functional receptor that is functionally
homologous to WT 5-HT2A. Further cross-talk studies, as described in Moreno et al. (2016),
could be used to verify the disruption of the heteromeric complex observed in the coimmunoprecipitation (Fig. 3). A failure or reduction in the Ca2+ signal induced by activation of
the mGlu2 receptor would confirm the results observed in this study, suggesting the heteromeric
interface has been disrupted significantly.
A potential explanation for the reduced signal detected in this study could be the 5-HT2ATM4ΔNF receptor does not properly get trafficked into the membrane, and therefore does not
form an interaction with mGlu2. This possibility was investigated using confocal fluorescence
microscopy, verifying the 2A/2C chimera showed proper subcellular localization following
translation. mCherry fluorescence was detected predominantly in the plasma membrane, with
other signals detected in unidentified cellular compartment(s). Before being trafficked into the
plasma membrane, 5-HT2A plasmids are first translated in the endoplasmic reticulum (ER).
Therefore, the concentrated fluorescence not surrounding the cell is likely localized in the ER.
To verify this, immunocytochemistry can be performed staining for an ER-resident protein (e.g.,
calreticulin) and the 5-HT2A-TM4ΔNF receptor.
It would also be interesting to image 5-HT2A-TM4ΔNF co-transfected with mGlu2 to verify the
disruption of the heteromer via an absence of co-localization as described in Gonzalez-Maeso et
al. (2008).
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This study utilized human embryonic kidney cells (HEK-293) as a heterologous expression
system, as it allows for highly reproducible results and maintains consistency with previous
studies investigating the 5-HT2A·mGlu2 complex in vitro (Moreno et al., 2012; Gonzalez-Maeso
et al., 2008; Thibado et al., 2021). It is appropriate to recognize a potential limitation when using
HEK-293 cells as an expression system. When cells are cultured for an extended period of time,
their health deteriorates. This has an effect on the cell’s growth rate and translation efficiency,
which might have a negative effect on the overall study, including the repeatability of results
(Thomas et al., 2005; Dumont et al., 2016). With this in mind, the maximum passage number
was kept below 20 throughout this study.
The main limitation of this study is the relatively small number of assays used to verify a
disruption in the heterocomplex. In terms of future research, it would be interesting to confirm
the current findings with biophysical assays such as BRET and FRET (Moreno et al., 2016). It
should be noted these methods most commonly used to assess GPCR homo- or heterodimerization, including co-immunoprecipitation, cannot demonstrate direct physical proximity
between two receptors. Protein to protein interactions detected by these techniques could instead
be facilitated by a third unknown protein that associates all the proteins into a larger complex,
rather than being in direct physical proximity between the two receptors.
Much work remains to be done before a complete understanding of the 5-HT2A·mGlu2
heteromeric interface is established. While this study provides valuable information on TM4
residues implicated in heteromer formation, alone, it does not provide sufficient evidence to
confirm the residues mutated in the 5-HT2A-TM4ΔNF form a direct interaction with mGlu2. As
the co-immunoprecipitation assay revealed a significant reduction in immunoreactivity but not
an absence of a band altogether, it can be assumed there may be other residues located in the C32

terminal end of TM4 that also mediate the formation of the 5-HT2A·mGlu2 complex. Therefore,
other constructs mutating non-homologous residues in the C-terminal half of TM4 could be
created and co-immunoprecipitated with mGlu2 to determine whether other residues also play a
role in mediating the heteromeric interface. It could also be possible not all four mutations found
in 5-HT2A-TM4ΔNF are necessary to disrupt the dimeric interface. This may be addressed by
introducing single point mutations of F4.43, L4.44, A4.47, and I4.48 to create four separate
constructs to determine whether one of these residues alone produces a significant disruption in
the co-immunoprecipitation signal. While the 5-HT2A-TM4ΔNF construct mutated four residues
in the N terminal half of TM4, it is possible even a partial mutant, where only two residues were
mutated (e.g., I4.47 and A4.48), could be sufficient in disrupting the binding interface of the
heteromer.
As 5-HT2C does not form a heterocomplex with mGlu2, it would also be interesting to introduce
the 5-HT2A receptor residues (F4.43, L4.44, A4.47, and I4.48) into the 5-HT2C receptor to try to
revive dimerization. This would provide further evidence for these residues' role in mediating the
heteromeric interface.
While commonly used methods to assess GPCR homo/heteromerization are mostly indirect
approaches, a photocrosslinking technique can identify individual amino acids that interact
physically at the heteromeric interface without compromising the overall structural integrity of
either protomer in the complex (Shah et al., 2020). For example, four new constructs correspond
to the four residues used to create the 5-HT2A-TM4NF construct, could be refined to include a
single photoreactive unnatural amino acid corresponding to F4.43, L4.44, A4.47, or I4.48
corresponding to each of the four new constructs. These constructs could then undergo UVmediated crosslinking, which would reveal whether one or more of the four residues mutated in
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this study form a direct interaction with mGlu2 and participate directly in establishing the
heteromeric interface of the 5-HT2A-mGlu2 complex.
Although the current results must be verified by future research, the present study has provided
clear evidence for the involvement of the N-terminal end of TM4 of the 5-HT2A receptor in its
heteromeric assembly with the mGlu2 receptor and provides a good starting point for further
studies.

Conclusion:
•

Sequence analysis of 5-HT2A-ΔTM4NF verifies the construct contains the 5-HT2C
receptor residues located at the N-terminal of the TM4.

•

Immunoblot experiments conducted in this study verify the similar expression of 5-HT2AΔTM4NF and WT 5-HT2A

•

5-HT2A-TM4NF/mGlu2 co-immunoprecipitation was significantly reduced, suggesting
the heteromeric interface had been disrupted.

•

Functional homology was verified through Ca2+ mobilization, displaying a similar pattern
of Ca2+ release between the 5-HT2A-ΔTM4NF and WT 5-HT2A

•

[3H]ketanserin binding confirmed receptor density and affinity similarity between 5HT2A-TM4NF and WT 5-HT2A.

•

Cytochemistry confirmed the 5-HT2A-ΔTM4NF mutant has proper subcellular
localization.

•

Further analysis to confirm the findings includes BRET, FRET, and fluorescent
microscopy of 5-HT2A-ΔTM4NF/mGlu2 co-transfected HEK-293 cells.
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•

Future work in using a photocrosslinking technique to identify the individual residues
responsible for the heteromeric interface
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